| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Vandetanib |
| Brand | Caprelsa® |
| Indication | For the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
| Assessment Process | |
| Rapid review commissioned | 06/06/2013 |
| Rapid review completed | 03/07/2013 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.